Boca Raton, Fla. – July 27, 2011 – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor and ZOLL Medical Corporation (NASDAQ GS: ZOLL), have entered into a licensing and development agreement.  ZOLL Medical Corporation is the leading global manufacturer of resuscitation and critical care devices and related software solutions, including professional defibrillators and automated external defibrillators (AEDs), the LifeVest ® Wearable Defibrillator , the AutoPulse ® Non-invasive Cardiac Support Pump, and Intravascular Temperature Management (IVTM™) equipment.   Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™ , an innovative, non-invasive diagnostic employing Vicor’s patented, proprietary PD2i ® nonlinear algorithm. Clinical use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i ® nonlinear algorithm as a valid metric for risk stratifying specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), trauma victims for imminent death absent immediate lifesaving intervention, and ICU patients for mortality risk stratification.

The agreement allows ZOLL to incorporate Vicor’s patented, proprietary PD2i ® nonlinear algorithm into ZOLL products to enable the ability to predict the risk of future serious events, such as sudden or imminent death in specific patient populations.  ZOLL will add Vicor’s PD2i ® technology in existing and future products to permit real